Comparative efficacy and safety of atezolizumab and bevacizumab between hepatocellular carcinoma patients with viral and non‐viral infection: A Japanese multicenter observational study-Reference-Cited by-同舟云学术

Comparative efficacy and safety of atezolizumab and bevacizumab between hepatocellular carcinoma patients with viral and non‐viral infection: A Japanese multicenter observational study

Published:2022-10-13 Issue:5 Volume:12 Page:5293-5303
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Medicine

Author:

Hatanaka Takeshi¹^ORCID,Kakizaki Satoru²³^ORCID,Hiraoka Atsushi⁴^ORCID,Tada Toshifumi⁵^ORCID,Hirooka Masashi⁶,Kariyama Kazuya⁷^ORCID,Tani Joji⁸,Atsukawa Masanori⁹,Takaguchi Koichi¹⁰,Itobayashi Ei¹¹,Fukunishi Shinya¹²,Tsuji Kunihiko¹³,Ishikawa Toru¹⁴,Tajiri Kazuto¹⁵^ORCID,Ochi Hironori¹⁶,Yasuda Satoshi¹⁷,Toyoda Hidenori¹⁷^ORCID,Ogawa Chikara¹⁸,Nishimura Takashi¹⁹^ORCID,Shimada Noritomo²⁰,Kawata Kazuhito²¹^ORCID,Kosaka Hisashi²²^ORCID,Tanaka Takaaki⁴,Ohama Hideko⁴,Nouso Kazuhiro⁷,Morishita Asahiro⁸^ORCID,Tsutsui Akemi¹⁰,Nagano Takuya¹⁰,Itokawa Norio⁹,Okubo Tomomi⁹,Arai Taeang⁹,Imai Michitaka¹⁴,Naganuma Atsushi²³^ORCID,Koizumi Yohei⁶,Nakamura Shinichiro⁵,Joko Kouji¹⁶,Kaibori Masaki²²^ORCID,Iijima Hiroko¹⁹,Hiasa Yoichi⁶^ORCID,Kumada Takashi²⁴^ORCID,

Affiliation:

1. Department of Gastroenterology Gunma Saiseikai Maebashi Hospital Maebashi Japan

2. Department of Clinical Research National Hospital Organization Takasaki General Medical Center Takasaki Japan

3. Department of Gastroenterology and Hepatology Gunma University Graduate School of Medicine Maebashi Japan

4. Gastroenterology Center Ehime Prefectural Central Hospital Matsuyama Japan

5. Department of Internal Medicine Japanese Red Cross Himeji Hospital Himeji Japan

6. Department of Gastroenterology and Metabology Ehime University Graduate School of Medicine Ehime Japan

7. Department of Gastroenterology Okayama City Hospital Okayama Japan

8. Department of Gastroenterology and Hepatology Kagawa University Kagawa Japan

9. Division of Gastroenterology and Hepatology, Department of Internal Medicine Nippon Medical School Tokyo Japan

10. Department of Hepatology Kagawa Prefectural Central Hospital Takamatsu Japan

11. Department of Gastroenterology Asahi General Hospital Asahi Japan

12. Premier Departmental Research of Medicine Osaka Medical and Pharmaceutical University Osaka Japan

13. Center of Gastroenterology Teine Keijinkai Hospital Sapporo Japan

14. Department of Gastroenterology Saiseikai Niigata Hospital Niigata Japan

15. Department of Gastroenterology Toyama University Hospital Toyama Japan

16. Center for Liver‐Biliary‐Pancreatic Disease Matsuyama Red Cross Hospital Matsuyama Japan

17. Department of Gastroenterology and Hepatology Ogaki Municipal Hospital Ogaki Japan

18. Department of Gastroenterology Japanese Red Cross Takamatsu Hospital Takamatsu Japan

19. Department of Internal Medicine, Division of Gastroenterology and Hepatology Hyogo College of Medicine Nishinomiya Japan

20. Division of Gastroenterology and Hepatology Otakanomori Hospital Kashiwa Japan

21. Hepatology Division, Department of Internal Medicine II Hamamatsu University School of Medicine Hamamatsu Japan

22. Department of Surgery Kansai Medical University Hirakata Japan

23. Department of Gastroenterology National Hospital Organization Takasaki General Medical Center Takasaki Japan

24. Department of Nursing Gifu Kyoritsu University Ogaki Japan

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.5337

Reference41 articles.

1. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

2. Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference

3. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline

4. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma

5. NASH limits anti-tumour surveillance in immunotherapy-treated HCC

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of Subgroups on Study Outcomes in Unresectable Hepatocellular Carcinoma Undergoing Upfront Systemic Treatment;American Journal of Clinical Oncology;2024-07-09

2. Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real‐world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial;Alimentary Pharmacology & Therapeutics;2024-05-08

3. Impact of underlying liver disease on unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors;BJC Reports;2024-01-29

4. Effectiveness and safety of atezolizumab-bevacizumab in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis;eClinicalMedicine;2023-09

5. Usefulness of Tumor Marker Score for Predicting the Prognosis of Hepatocellular Carcinoma Patients Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study;Cancers;2023-08-31